ClinicalTrials.gg
RecruitingNCT06108050Updated Dec 16, 2025

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

A Phase 1 interventional study of JZP898 and Pembrolizumab in Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jazz Pharmaceuticals. Recruiting at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-16.

Sponsored by Jazz Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
177
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
337th of 1,865
177 · median 43
Started
2023
with 101 others
Phase 1
710 of 2,056
128 open now
Primary completion
2027-11
later than 310 of 541 live
Registered
1,820th of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 337th largest by planned enrollment of the 1,865 interventional ones that give a count, is one of 102 that started in 2023, is one of 710 in phase 1, reaches primary completion later than 310 of the 541 other live ones, and was the 1,820th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combination with pembrolizumab in adult participants with advanced or metastatic solid tumors.

Read the detailed description

Two-part study: Part A Dose Exploration (Parts A1 and A2) and Part B Combination Expansion.

Part A Dose Exploration:

  • Part A1 - a monotherapy dose exploration to determine the monotherapy recommended dose and/or maximum tolerated dose (MTD) (or highest cleared dose level) and safety profile of JZP898.
  • Part A2 - a combination dose exploration of JZP898 plus pembrolizumab to determine the CombiRD (combination recommended dose for expansion).

Part B Combination Expansion:

  • Part B - combination expansion using a basket design to evaluate clinical antitumor activity and safety profile of JZP898 in combination with pembrolizumab at the CombiRD identified in Part A2.
03

Conditions studied

  • Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • Advanced Solid Tumor
  • Metastatic Solid Tumor
  • JZP898
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult ≥ 18 years of age
  • Histological or cytological diagnosis of advanced or solid tumor.

    1. Previously treated participants with solid tumors that are amenable to CPI therapy (eg. NSCLC, melanoma, HNSCC, RCC, HCC, gastroesophageal carcinomas, UC, or CRC [MSI-H]) for whom, in the opinion of the investigator, there is no SoC available to convey clinical benefit.
    2. Parts A2 and B: previously-treated (≥ 1 line of prior anticancer therapy) participants with select tumor types (NSCLC, HNSCC, melanomas, RCC, and UC) who have progressed on/after prior CPI therapy based on investigator assessment per version 1.1.
  • Participants in select tumor types:

    1. NSCLC: eligible for platinum-based therapy and received platinum-based therapy prior to inclusion in the study.
    2. HNSCC: eligible for platinum therapy and received platinum-based therapy prior to inclusion in this study.
    3. Melanoma with known BRAFv600 mutation: received BRAF/MEKi therapy before this study.
  • score of 0 to 1.
  • per RECIST version 1.1 criteria.
  • Parts A1 and A2 only: willing to consent to mandatory tumor (both pretreatment and post-treatment with JZP898) unless medically infeasible
  • Adequate organ and bone marrow function as indicated by the following laboratory values (within 4 weeks prior to starting the study interventions)
  • Men and women of to observe highly effective for the duration of treatment and for 4 months following the last dose of study drug;
  • Additional criteria may apply

Exclusion criteria

Exclusion Criteria

  • Unresolved toxicities from previous therapy that is > Grade 1.
  • to mAb, IFNα, or study intervention components.
  • Primary CNS tumor or symptomatic .
  • Have a second primary treated within the previous 2 years (exceptions: non-, non-melanomatous skin cancers, carcinoma in-situ, and melanoma in-situ).
  • Active disease (in the last 2 years) requiring systemic or agents.
  • Active or history of pneumonitis (noninfectious) or interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease.
  • Any history of suicidal behavior or any suicidal ideation
  • ischemic/hemorrhagic cerebrovascular accident/stroke and/or clinically significant active cardiovascular disease
  • Received any anticancer therapy within 5 half-lives or 4 weeks (whichever is shorter) prior to the first dose of study drug
  • Received prior radiotherapy within 2 weeks of the first dose of study drug or have had a history of radiation pneumonitis
  • Major surgery within 2 weeks prior to the first dose of study intervention.
  • Participant is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study
  • Had a stem cell/solid organ transplant.
  • Receipt of prior IFNα therapy
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
177 participants (estimated)

Study arms

  • Experimental
    Part A1 Dose Exploration: JZP898 monotherapy

    Drug: JZP898

  • Experimental
    Part A2 Dose Exploration: JZP898 in combination with pembrolizumab

    Drug: JZP898 · Drug: Pembrolizumab

  • Experimental
    Part B Combination Expansion: JZP898 in combination with pembrolizumab

    Drug: JZP898 · Drug: Pembrolizumab

Interventions

  • DrugJZP898

    Investigational drug monotherapy

  • Anti-PD1 antibody

06

What researchers measure

Primary outcomes

  1. Number of Participants with Dose Limiting Toxicities in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  2. Incidence of TEAEs and SAEs in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  3. Incidence of dose interruptions, discontinuation, and reductions due to TEAEs in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  4. Objective Response Rate (ORR) As Assessed by the Investigator In Combination Therapy

    Time frame: Up to 36 months

Secondary outcomes

  1. Pharmacokinetic Parameter: Maximum Concentration (Cmax) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  2. Pharmacokinetic Parameter: Time to Maximum Concentration (Tmax) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  3. Pharmacokinetic Parameter: Terminal Elimination Half-life (t½) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  4. Pharmacokinetic Parameter: Area Under the Concentration-Time Curve (AUC) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  5. Pharmacokinetic Parameter: Clearance (CL) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  6. Pharmacokinetic Parameter: Volume of Distribution (V) of JZP898 in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  7. Pharmacokinetic Parameter: Activated IFNα-to-JZP898 Ratio in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  8. Pharmacokinetic Parameter: Accumulation ratio for Cmax in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  9. Pharmacokinetic Parameter: Accumulation Ratio for AUC in Monotherapy and Combination Therapy

    Time frame: Up to 36 months

  10. ORR As Assessed by the Investigator in Monotherapy

    Time frame: Up to 36 months

  11. Duration of Response (DoR) As Assessed by the Investigator

    Time frame: Up to 36 months

  12. Disease Control Rate (DCR) As Assessed by the Investigator

    Time frame: Up to 36 months

  13. Progression-free Survival (PFS) As Assessed by the Investigator

    Time frame: Up to 36 months

  14. Overall Survival (OS)

    Time frame: Up to 36 months

  15. Incidence of ADAs towards JZP898

    Time frame: Up to 36 months

07

Study locations

10 of 10 sites recruiting
  • California Cancer Associates for Research and Excellence
    Encinitas, California 92024, United States
    Recruiting
  • California Cancer Associates for Research and Excellence
    Fresno, California 93270, United States
    Recruiting
  • Sarah Cannon Research Institute at HealthONE
    Denver, Colorado 80218, United States
    Recruiting
  • Florida Cancer Specialists
    Orlando, Florida 32827, United States
    Recruiting
  • Duke University Medical Center - Duke Cancer Institute
    Durham, North Carolina 27710, United States
    Recruiting
  • Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
    Recruiting
  • SCRI Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
  • Texas Oncology - Baylor Charles A Sammons Cancer Center
    Dallas, Texas 75246, United States
    Recruiting
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
    Recruiting
  • Virginia Cancer Specialists
    Fairfax, Virginia 22031, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Nov 2027, 48 months after the start.

Of 288 industry-sponsored phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 75. This study's planned 48 months is close to that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2023
First posted
Oct 30, 2023
StartActual
Nov 7, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
May 31, 2028
Last update
Dec 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06108050
Responsible party
Sponsor
First posted
Oct 30, 2023
Start date
Nov 7, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Dec 16, 2025

Study contacts

Clinical Trial Disclosure & Transparency
Contact
ClinicalTrialDisclosure@JazzPharma.com
215-832-3750

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion